Royalty Report: Drugs, Therapeutic, Delivery – Collection: 209558

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Delivery
  • Hormones

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 209558

License Grant
For Oral Cavity Products, Licensor grants an exclusive worldwide license under the Licensors Patent Rights and the Technology to make, have made, use, sell, have sold and otherwise commercialize Oral Cavity Products, which exclusive license shall be exclusive as to all other Entities including, without limitation, Licensor.

For Non-Oral Cavity Products, Licensor grants a non-exclusive worldwide license under the Licensor Patent Rights and the Technology to make, have made, use, sell, have sold and otherwise commercialize Non-Oral Cavity Products.

License Property
Licensor owns certain patent rights having claims covering inventions and improvements relating to Minocin Periodontal and ACYs related drug delivery technologies.  The Product means any Oral Cavity Product or Non-Oral Cavity Product.  MP means the poly-glycolide-lactide micro capsules containing minocycline.

Minocin Periodontal technologies may be used in the treatment of diseases of the oral cavity.

ACY's technologies include certain drug delivery technologies that may be used in connection with other pharmaceutical products for the treatment of diseases both within and outside of the oral cavity.

Field of Use
The Licensee is engaged, among other things, in the business of developing and commercializing pharmaceutical products for the treatment of diseases of the oral cavity, including dental and periodontal applications.

IPSCIO Record ID: 245912

License Grant
The Swiss Licensor grants an exclusive, world-wide sublicense to use the Technology in the oral cavity.
License Property
The licensed technology relates to Decapeptyl, D-Trp6-LHRH.
Field of Use
The use is in the field of the oral cavity.

IPSCIO Record ID: 202864

License Grant
The Parties agree to continue their collaboration on research and development programs to research the use of the Licensor's Technology for oral delivery of parathyroid hormone molecule and human growth hormone molecules (excluding calcitonin) and human growth hormone molecules (not to include secretagogues) and mimetics (PTH and HGH), as well as to study the potential for the Licensors Technology to improve non-oral administration routes, including, but not limited to, the injectable (sub-cutaneous, intra-venous, intra-muscular, intra-peritoneal and depot), buccal, nasal, ocular, pulmonary, transdermal and vaginal administration routes (the 'Non-Oral Routes') of proteins all as more specifically set forth in the PTH and HGH Work Plans. Licensor will make available to Lilly access to all Licensor Technology relevant for the Program.
License Property
Licensor is engaged in the research and development of proprietary synthetic chemical compounds that enable the delivery of therapeutic macromolecules and other compounds that are not currently deliverable by oral means or by certain non-oral means.

The strategic alliance is to develop oral formulations of ForTeo (recombinant parathyroid hormone) and Humatrope (human growth hormone (HGH)) utilizing the Licensor's proprietary drug delivery technology.

Field of Use
Licensee is engaged in research to produce, therapeutic macromolecules and other compounds that are not currently deliverable by oral means or by certain non-oral means.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.